« | Home | »

FDA approves Sitvarga for Treating Liver Cancer

By jeremyc | April 30, 2017

The FDA has expanded the approved use of Sitvarga. Now this drug can be used for treating liver cancer patients who have had undergone treatment with sorafenib. The FDA has approved a new liver cancer treatment in almost ten years.

Liver cancer patients don’t have many treatment options available to them. Now, for the first time liver cancer patients have access to a treatment approved by FDA which they can use in the initial treatment with the drug sorafenib stops giving results.

It is estimated that nearly 40,000 people in the U.S. will be diagnosed with the cancer of the liver in 2017 and nearly 28,900 people will die from it.

Sitvarga blocks many enzymes which facilitated cancer growth. It is also used for treating patients with gastrointestinal stromal tumors or colorectal cancer.

The effectiveness and safety of Sitvarga was analyzed in a trial involving 573 liver cancer patients. Compared to patients who received a placebo, liver cancer patients who received Sitvarga had a greater overall response rate and progression-free survival period.

Like other drugs, Sitvarga use can cause side effects. Most common side effects include pain, fatigue, hypertension, decreased appetite, difficulty speaking, and infection.


Topics: | FDA | No Comments »

Comments are closed.